Wedmont Private Capital’s Recursion Pharmaceuticals RXRX Stock Holding History

Wedmont Private Capital’s Portfolio RXRX Stock Details RXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$74.8K	Hold	18,943	–	–	﹤0.01%	1000
2026 Q2	$67.4K	Hold	18,943	–	–	﹤0.01%	947
2026 Q1	$64.2K	Hold	18,943	–	–	﹤0.01%	835
2025 Q4	$92.1K	Sell	18,943 -2,000	-10%	-$9.91K	﹤0.01%	799
2025 Q3	$110K	Hold	20,943	–	–	﹤0.01%	780
2025 Q2	$117K	Hold	20,943	–	–	0.01%	731
2025 Q1	$121K	Hold	20,943	–	–	0.01%	681
2024 Q4	$144K	Buy	20,943 +2,000	+11%	+$13.4K	0.01%	683
2024 Q3	$117K	Hold	18,943	–	–	0.01%	652
2024 Q2	$158K	Hold	18,943	–	–	0.01%	620
2024 Q1	$172K	Buy	18,943 +2,000	+12%	+$22.3K	0.01%	578
2023 Q4	$214K	Hold	16,943	–	–	0.02%	513
2023 Q3	$115K	Hold	16,943	–	–	0.01%	487
2023 Q2	$202K	Buy	+16,943	New	+$119K	0.02%	474

Other funds holding RXRX

GAA

Green Alpha Advisors Niwot, Colorado $148M AUM 98.22% 1-Year Est. Return

CCIA

Cherry Creek Investment Advisors Englewood, Colorado $261M AUM 29.65% 1-Year Est. Return

WWM

Whalen Wealth Management Las Vegas, Nevada $234M AUM 28.06% 1-Year Est. Return

Kieckhefer Group Mequon, Wisconsin $252M AUM 40.97% 1-Year Est. Return

AWM

Accel Wealth Management Waverly, Iowa $464M AUM 21.88% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return

TWM

TriaGen Wealth Management Calabasas, California $413M AUM 35.91% 1-Year Est. Return

FFA

Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return

CoreCap Advisors Southfield, Michigan $3.48B AUM 21.43% 1-Year Est. Return

QPBE

Quintet Private Bank (Europe) Luxembourg $2.28B AUM 23.89% 1-Year Est. Return

Wedmont Private Capital's RXRX Position: Q3 2026 in Review

Wedmont Private Capital held its Recursion Pharmaceuticals (RXRX) position steady in Q3 2026 at 18,943 shares worth $74.8K. The position accounts for ﹤0.01% of the portfolio, ranked #1000.

Wedmont Private Capital first reported a position in RXRX in Q2 2023 and has held it in 14 quarters since. The position peaked at $214K in Q4 2023. 20 funds tracked by Wall St. Rank hold RXRX as of Q3 2026.

Wedmont Private Capital held 18,943 shares of Recursion Pharmaceuticals worth $74.8K as of Q3 2026.
Wedmont Private Capital left its Recursion Pharmaceuticals share count unchanged in Q3 2026.
Recursion Pharmaceuticals made up ﹤0.01% of Wedmont Private Capital's portfolio in Q3 2026, its #1000 holding.
Wedmont Private Capital first reported a position in Recursion Pharmaceuticals in Q2 2023 and has held it in 14 quarters since.
Wedmont Private Capital's Recursion Pharmaceuticals position peaked at $214K in Q4 2023.
20 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q3 2026.

Based on Wedmont Private Capital's 13F filing for Q3 2026, filed 9 Oct 2026.